Field evaluation of seven SARS-COV-2 antigen assays

Abstract

There is a global demand for rapid diagnostic tests (RDTs) for Coronavirus disease 2019 (COVID-19), and the interest in their clinical compliance is growing. In this study, we evaluated the clinical compliance of seven different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen RDTs. Nasopharyngeal/oropharyngeal swab specimens from COVID-19-confirmed cases and reverse-transcription PCR (RT-PCR) screening were used to evaluate the performance of seven RDTs. Using the RT-PCR and RDT results, we predicted the cycle threshold (Ct) of each target gene (E, RdRP, and N genes) which 50% (Ct50) and 95% (Ct95) detection rates were achieved in the RDTs. A total of 482 specimens were enrolled in our study: 316 specimens from COVID-19-confirmed cases and 166 RT-PCR-negative specimens. The median values of Ct50 and Ct95 for the seven RDTs were in the ranges of ranged 24.3–30.9 and 19.3–22.6 for E, 25.5–31.5 and 20.9–24.0 for RdRP, and 26.8–32.3 and 22.7–25.7 for N, respectively. The RDTs showed acceptable compliance only for specimens with high viral burdens (Ct 30). These results suggest that RDTs should not be used without molecular assays for COVID-19 screening for asymptomatic patients because of their high false-negative rates.

Keywords

• COVID-19
• SARS-CoV-2
• Rapid diagnostic test
• Evaluation